hi, tech

Nike swooshes into Houston with new technically enhanced store

Get your kicks at this new techy Nike locale. Photo courtesy of Nike by CityCentre

Heads up, Houston sneakerheads. The world’s largest shoe brand is kicking it with a new, digitally enabled local outpost. Nike by CityCentre opened on March 17, promising a techy approach to buying those choice high tops, low courts, and Jays (that’s Air Jordans in sneakerspeak).

This new, 5,298 square-foot store (822 Town and Country Blvd. Suite 106) will pay particularly close attention to female shoppers. Women can enjoy one-on-one time with store athletes for product knowledge, bra fitting, and styling sessions, per a press release. Ladies can also find an assortment of expanded performance bras and leggings.

What makes the new shop techy? The CityCentre locale will offer Nike’s SNKRS PASS on the Nike SNKRS App, which uses GPS location to determine if a nearby Nike location has their preferred style available in their size.

Rather than calling, shoppers can link up with in-store staff using Swoosh Text, an SMS messaging service, to check inventory, get product recommendations, and more.

But, it’s all about the fit and sneaks, no? Nike by CityCentre will sport footwear such as Air Force 1s, Air Max 90’s, and more, a press release notes. Popular Jordan footwear styles and clothes for men and women will also satisfy those obsessed with the Swoosh.

Noting in a press release that the company is committed to the local community, Nike by CityCentre aims to be staffed by at least 50 percent Houston-area staff.

Photo courtesy of Nike by CityCentre

---

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News